EUCTR2012-003590-25-IT进行中（未招募）1 期
Phase II study of the Pan-HER inhibitor Dacomitinib (PF-00299804) for patients with locally advanced or metastatic squamous cell carcinoma of the penis - HER-URO01
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点目标入组 37 人开始时间: 2012年11月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Cytologically or histologically proven diagnosis of SCC of the penis.
- •Histologically (Tru-cut biopsy) proven diagnosis of loco-regional nodal disease will be required in all cases except for those with unequivocal lymphadenopathy.
- •Uni- or bidimensionally measurable disease.
- •Clinical stage N2-3 and/or M1 (TNM 2002).
- •Locoregional relapse after prior major surgery/ies (either single or multiple).
- •Age 18-75.
- •Written informed consent.
- •ECOG performance status of at least 1.
- •Neither prior chemotherapy nor treatment with any targeted agent.
- •No use of any investigational agents within 4 weeks of study inclusion.
- •Adequate bone marrow, liver and renal function.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •Excluded Medical Conditions
- •History of any one or more of the following cardiovascular conditions within the past 6 months:
- •oCardiac angioplasty or stenting.
- •oMyocardial infarction.
- •oUnstable angina.
- •oCoronary artery by-pass graft surgery.
- •oSymptomatic peripheral vascular disease.
- •oClass III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
- •oCardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted).
- •oScreening ECG with a QTc>450 msec, congenital long QT syndrome, history of sustained ventricular tachycardia, history of ventricular fibrillation or torsade de pointes, bradycardia defined as heart rate < 50 bpm (patients with a pacemaker and heart rate > 50 bpm are eligible).
- •oUncontrolled hypertension.
- •History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug.
- •History of HIV infection or active chronic hepatitis B or C.
- •Active clinically serious infections (> grade 2 NCI-CTC version 4.0).
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics).
- •History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- •Patients undergoing renal dialysis.
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma or any cancer curatively treated > 5 years prior to study entry.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.
- •Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
- •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
- •Patients unable to swallow oral medications.
- •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug.
- •Excluded therapies and medications, previous and concomitant
- •Treatment with any of the following anti-cancer therapies:
- •oradiation therapy, surgery or tumor embolization within 14 days prior to the first dose of PF-299804 OR
- •ochemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of PF-299804.
- •(Palliative radiotherapy will be allowed).
- •Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study].
- •Prior exposure to study drug.
研究者
相似试验
已完成
不适用
Phase I/II study with the combination of dacomitinib and PD-0325901 in metastatic KRAS mutation positive non-small cell lung cancer10027476non-small cell lung cancerNL-OMON47225Antoni van Leeuwenhoek Ziekenhuis132
进行中（未招募）
1 期
Phase I/II study with the combination of dacomitinib and PD-0325901 in metastatic non-small cell lung cancer with a mutation in the KRAS genenon-small cell lung cancerEUCTR2013-003299-10-NLThe Netherlands Cancer Institute132
Unknown
2 期
Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell CancerSkin Squamous Cell CancerNCT02268747Fondazione IRCCS Istituto Nazionale dei Tumori, Milano43
已完成
2 期
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The LungCarcinoma, Non-small CellNCT00818441Pfizer119
进行中（未招募）
不适用
Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancerHormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+)EUCTR2005-004294-21-BEFresenius Biotech GmbH40